Cargando…
Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
Cancer is the second leading cause of death in the United States with 1.7 million new cases estimated to be diagnosed in 2016. This disease remains a formidable clinical challenge and represents a substantial financial burden to the US health care system. Therefore, research and development of novel...
Autores principales: | Ladin, Daniel A., Soliman, Eman, Griffin, LaToya, Van Dross, Rukiyah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054289/ https://www.ncbi.nlm.nih.gov/pubmed/27774065 http://dx.doi.org/10.3389/fphar.2016.00361 |
Ejemplares similares
-
Corrigendum: Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
por: Ladin, Daniel A., et al.
Publicado: (2021) -
Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms
por: Soderstrom, Ken, et al.
Publicado: (2017) -
Apoptosis mechanisms induced by 15d-PMJ(2) in HCT116 colon cancer cells: insights into CHOP10/TRB3/Akt signaling
por: Albassam, Hussam, et al.
Publicado: (2023) -
Damage-associated molecular pattern (DAMP) activation in melanoma: investigation of the immunogenic activity of 15-deoxy, Δ(12,14) prostamide J(2)
por: Elhassanny, Ahmed, et al.
Publicado: (2020) -
Kinin B1R Activation Induces Endoplasmic Reticulum Stress in Primary Hypothalamic Neurons
por: White, Acacia, et al.
Publicado: (2022)